GcMAF
20 ACTIONS
1. Activates Macrophages
2. Apoptosis
3. Stop metastasis
4. Increases energy production (mitochondria)
5. Improves actions of neurons in the brain
6. Create neurons along with glial cells
7. Counters toxic effects (radioactive cadmium)
8.
1. Activates Macrophages
2. Apoptosis
3. Stop metastasis
4. Increases energy production (mitochondria)
5. Improves actions of neurons in the brain
6. Create neurons along with glial cells
7. Counters toxic effects (radioactive cadmium)
8.
http://gcmaf.timsmithmd.com/book/book/4/
http://gcmaf.timsmithmd.com/book/chapter/42/
http://gcmaf.timsmithmd.com/book/chapter/43/
http://gcmaf.timsmithmd.com/book/chapter/44/
http://gcmaf.timsmithmd.com/book/chapter/45/
http://gcmaf.timsmithmd.com/book/chapter/46/
http://gcmaf.timsmithmd.com/book/chapter/47/
http://gcmaf.timsmithmd.com/book/chapter/48/
http://gcmaf.timsmithmd.com/book/chapter/49/
http://gcmaf.timsmithmd.com/book/chapter/50/
http://gcmaf.timsmithmd.com/book/chapter/51/
http://gcmaf.timsmithmd.com/book/chapter/52/
http://gcmaf.timsmithmd.com/book/chapter/53/
http://gcmaf.timsmithmd.com/book/chapter/54/
http://gcmaf.timsmithmd.com/book/chapter/55/
http://gcmaf.timsmithmd.com/book/chapter/56/
http://gcmaf.timsmithmd.com/book/chapter/57/
http://gcmaf.timsmithmd.com/book/chapter/58/
http://gcmaf.timsmithmd.com/book/chapter/59/
http://gcmaf.timsmithmd.com/book/chapter/60/
http://gcmaf.timsmithmd.com/book/chapter/61/
http://gcmaf.timsmithmd.com/book/chapter/62/
http://gcmaf.timsmithmd.com/book/chapter/63/
http://gcmaf.timsmithmd.com/book/chapter/64/
http://gcmaf.timsmithmd.com/book/chapter/65/
http://gcmaf.timsmithmd.com/book/chapter/66/
http://gcmaf.timsmithmd.com/book/chapter/67/
http://gcmaf.timsmithmd.com/book/chapter/68/
Dr. Yamamoto’s 2008 breast cancer paper entitled: “Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).” (This is an abstract. You can access the full paper by clicking in upper right-hand corner.
| breast_cancer.pdf |
Dr. Yamamoto’s 2008 prostate cancer paper entitled: “Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.”
| prostate_cancer.pdf |
Dr. Yamamoto’s 2008 colorectal cancer paper entitled: “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.” (This is an abstract. You can access the full paper by clicking in upper right-hand corner.)
Dr. Yamamoto’s 2008 HIV paper entitled: “Immunotherapy of HIV-Infected Patients With Gc Protein-Derived Macrophage Activating Factor (GcMAF).”
| hiv.pdf |
Nobuto Yamamoto References
Nobuto Yamamoto, Naofumi, Ushijima, and Yoshihiko Koga. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). Serum Gc protein (known as vitamin D3-binding protein) is the precursor. J Med Virol. Jan; 81(1):16-26. 2009.
Yamamoto N, Suyama H, Nakazato H, Yamamoto N-Y, Koga Y. 2008c. Immunotherapy of metastatic colorectal cancer with vitamin Dbinding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 57:1007–1016.
Yamamoto N, Suyama H, Yamamoto N-Y. 2008b. Immunotherapy of prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Translational Oncol 1:65–72.
Yamamoto N, Suyama H, Yamamoto N-Y, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage-activating factor, (GcMAF). Int J Cancer 2008 Jan 15;122(2):461-7.
Yamamoto N, Ueda M, Benson CE. 2007. Treatment of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF) eradicates HIV-infection. Proc 13th Int Cong Immunol. Italy: Medimond, Bologna. pp. 35–38.
Nobuto Yamamoto, Masahiro Urade, Yoshihiko Koga, Nobuyuki Yamamoto, Theodor Sery and Masumi Ueda. Macrophages Activated By GCMAF Develop Enormous Variation of Receptors That Recognize and Eradicate Adenocarcinomas. Clinical Immunology, Volume 119, Supplement 1, 2006, Page S96. FOCIS 2006 Abstract Supplement - 6th Annual Meeting.
Yamamoto, Masahiro Urade, Yoshihiko Koga, Nobuyuki Yamamoto, Theodor Sery and Masumi Ueda. Macrophages Activated By GCMAF Develop Enormous Variation of Receptors That Recognize and Eradicate Adenocarcinomas. Nobuto 2006.
Yamamoto N.. Pathogenic significance of a-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Human Retroviruses 22:262–271, 2006.
Yamamoto N, Urade M. 2005. Pathogenic significance of a-Nacetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 7:674–681.
Yamamoto N, Urade M, Ueda M. 2005. Potent tumoricidal capacity of macrophages activated by Gc protein-derived macrophage activating factor (GcMAF) and its therapeutic efficacy for prostate, breast, and colorectal cancers. J Immunother 28:642.
Nobuto Yamamoto, Masahiro Urade. Microbes and infection. Institut Pasteur 7 , 4: 674-81, Apr 2005
Yamamoto N, Ueda M. 2004b. Eradication of HIV by treatment ofHIVinfected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology. Italy: Medmond, Bologna. pp. 197–200.
Yamamoto N, Ueda M. 2004a. Therapeutic efficacy of vitamin Dbinding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology. Italy: Medmond, Bologna. pp. 201–204.
Nobuto Yamamoto and Masumi Ueda. Cancer cell-killing by macrophages treated with Gc protein-derived macrophage activating factor (GcMAF) Proc Amer Assoc Cancer Res, Volume 45, 2004. Experimental and Molecular Therapeutics 11: Specific Immune Mechanisms and Cancer Vaccines: Clinical Studies Abstract #1255
Yamamoto N. 2002. Preparation of potent macrophage activating factor derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis. U.S. Patent Number: 6,410,269.
Shigeru Kanda, Yasushi Mochizuki, Yasuyoshi Miyata, Hiroshi Kanetake, Nobuto Yamamoto. Effects of Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) on Angiogenesis. Journal of the National Cancer Institute, Vol. 94, No. 17, 1311-1319, September 4, 2002.
Koga Y, Naraparaju VR, Yamamoto N. 1999. Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 220:20–26.
Yamamoto N. 1999. Diagnostic and prognostic ELISA assays of serum a-N-acetylgalactosaminidase for AIDS. U.S. Patent Number: 5,985,545.
Yamamoto N. 1998b. Diagnostic and prognostic ELISA assays of serum or plasma a-N-acetylgalactosaminidase for cancer. U.S. Patent Number: 5,712,104.
Yamamoto N, Naraparaju VR. 1998. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 76:237–244.
Yamamoto, Nabuto; Naraparaju, Venka Tenkateswara, R. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Special Feature. Immunology & Cell Biology. 76(3):237-244, June 1998.
Nobuto Yamamoto, Venkateswara R. Naraparaju and Masahiro Urade. Prognostic Utility of Serum a-N-Acetylgalactosaminidase and Immunosuppression Resulted from Deglycosylation of Serum Gc Protein in Oral Cancer Patients. Cancer Research 57, 295-299, January 15, 1997.
Yamamoto N. 1997. Diagnostic and prognostic indices for cancer and AIDS. U.S. Patent Number: 5,620,846. Yamamoto N. 1998a. Vitamin D and the immune system. In: Encyclopedia of Immunology. 2nd edition. Delves PJ, Roitt I, editors. Academic Press Ltd. London: pp. 2494–2499.
Yamamoto N, Naraparaju VR, Urade M. 1997. Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57:295–299.
Yamamoto N, Naraparaju VR. 1997. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D3-binding proteinderived macrophage activating factor. Cancer Res 57:2187–2192.
Nobuto Yamamoto, Venkateswara R. Naraparaju, Mary Moore and Lawrence H. Brent. Deglycosylation of Serum Vitamin D3-Binding Protein by alpha-N Acetylgalactosaminidase Detected in the Plasma of Patients with Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology Volume 82, Issue 3, March 1997, Pages 290-298.
Korbelik M, Naraparaju VR, and Yamamoto N (1997). Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75, 202 – 207.
Yamamoto, N., Naraparaju, V. R., and Asbell, S. 0. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res.,56:2827-2831,1996.
Yamamoto, N., and Naraparaju, V. R. Role of mouse vitamin D3-binding protein in activationof macrophages. J. Immunol.,157: 1744-1751,1996.
Yamamoto N. 1996. Structural definition of a potent macrophage activating factor derived from vitamin D3 binding protein with adjuvant activity for antibody production. Mol Immunol 33:1157–1164.
Koga, Y., Naraparaju, V. R., and Yamamoto, N. Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Cancer Research Proc., 37: 481, 1996.
Yamamoto, N., Naraparaju, V. R., and Srinivasula, S. M. Structural modification of serum vitamin D1-binding protein and immunosuppression in AIDS patients. AIDS Ret. Hum. Retroviruses, 11: 1373-1378,1995.
Yamamoto. N., Willen, N. P., and Lindsay, D. D. Participation of serum proteins in the inflammation-primed activation of macrophages.Inflammation, 8: 311-322, 1994.
Naraparaju VR, Yamamoto N. 1994. Roles of b-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation primed activation of macrophages. Immunol Lett 43:143–148.
Yamamoto N, Kumashiro R.. Conversion of vitamin D3 binding protein (Group! specific component) to a macrophage activating factor by the stepwise action of b-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794–2802, 1993.
Yamamoto N. 1993. In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor. U.S. Patent Number: 5,177,002.
Homma, S., Yamamoto, M., and Yamamoto, N. Vitamin D binding protein (group specific componen is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol. Cell Biol.,71: 249-257, 1993.
Yamamoto, N., Kumashiro, R., Yamamoto, M., Willett, N. P., and Lindsay, D. D. Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Inf. Imm., 61: 5388-5391, 1993.
Yamamoto, N., and Homma, S. Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes.Proc. NatI. Acad. Sci. USA, 88: 8539-8543, 1991.
Yamamoto N, Homma S, Millman I. 1991. Identification of the serum factor required for in vitro activation of macrophages: Role of vitamin D3 binding protein (Group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147:273–280.
Yamamoto N, Homma S. 1991. Vitamin D3 binding protein (groupspecific component,Gc) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88:539–543.
Homma S, Yamamoto N. 1990. Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 79:307–313.
Ngwenya, B. Z., and Yamamoto, N. Contribution of lysophosphatidylcholine-treated nonadherent cells to mechanism of macrophage activation. Proc. Soc. Exp. Biol. Med.,193:118-124, 1990.
Yamamoto N, St., Claire DA, Homma S, Ngwenya BZ. 1988. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 48:6044–6049.
Matsui T, Nakashima H, Yoshiyama H, Kobayashi N, Yamamoto N. 1987. Plaque staining assay for non- or weakly cytotoxic human immunodeficiency virus. J Clin Microbiol 25:1305–1307.
Yamamoto, N., Ngwenya, B. Z., Sery, 1. W., and Pieringer R. A. Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol. Immunother. 2,5: 185-192, 1987.
Yamamoto, N., and Ngwenya, B. Z. Activation of macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids. Cancer Res., 47: 2008-2013,1987.
Ngwenya, B. Z., and Yamamoto N. Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol. Immunother., 21: 1074-1082, 1986.
Harada S, Purtilo D, Koyanagi Y, Sonnabend J, Yamamoto N. 1986. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV). J Immnol Methods 92:177–181.
Ngwenya, B. Z., and Yamamoto, N. Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim. Biophys. Acts 839: 9-15,1985.
Sato M, Tanaka H, Yamada T, Yamamoto N. 1977. Persistent infection of BHK/WI-2 cells with rubella virus and characterization rubella variants. Arch Virol 54:333–343.
Korbelik M, Naraparaju VR, and Yamamoto N (1997). Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75, 202 – 207.
Yamamoto N, and Homma S (1991). Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88, 8539 – 43.
Yamamoto N, Hoober JK, Yamamoto N, and Yamamoto S (1992). Tumoricidal capacities of macrophages photodynamically activated with hematoporphoryin derivative. Photochem Photobiol 56, 245 – 50.
Yamamoto N, and Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D- binding protein -derived macrophage activating factor. Cancer Res 57, 2187–92, 1997.
Koga Y, Naraparaju VR, and Yamamoto N (1999). Antitumor effect of vitamin D- binding protein - derived macrophage activating factor on Ehrlich ascites tumor - bearing mice. Proc Soc Exp Biol Med 220, 20–26.
Other references
Fidler IJ. Therapy of disseminated melanoma by liposome-activated macrophages. World J Surg. 1992 Mar-Apr;16(2):270-6.
Fidler IJ. Macrophage therapy of cancer metastasis. Ciba Found Symp. 1988;141:211-22.
Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Ther. 1998 Jun;78(3):141-54.
Killion JJ, Fidler IJ. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Immunomethods. 1994 Jun;4(3):273-9.
Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 1998 Mar;17(1):55-75.
Liposomal delivery of biological response modifiers to macrophages. Pak CC, Fidler IJ. Biotherapy. 1991;3(1):55-64.
Macrophages in cancer metastases and their relevance to metastatic growth. Key ME. Cancer Metastasis Rev. 1983;2(1):75-88.
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38.
Drug delivery to macrophages for the therapy of cancer and infectious diseases. Kirsh R, Bugelski PJ, Poste G. Ann N Y Acad Sci. 1987;507:141-54. Review.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
Origin of cancer metastases and its implications for therapy. Fidler IJ. Isr J Med Sci. 1988 Sep-Oct;24(9-10):456-63.
Poste G. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep. 1986 Jan;70(1):183-99. Review.
Tumor cell diversity and host responses in cancer metastasis—part II—host immune responses and therapy of metastases. Nicolson GL, Poste G. Curr Probl Cancer. 1983 Jan;7(7):1-42. Review.
Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol. 1996 Jun;59(6):797-803.
Withers HR, Lee SP. Semin. Modeling growth kinetics and statistical distribution of oligometastases. Radiat Oncol. 2006 Apr;16(2):111-9.
Fidler IJ, Poste G. Springer Semin. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Immunopathol. 1982;5(2):161-74. Review.
Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol. 1999;43 Suppl:S3-10.
Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005 Jan;173(1):10-20.
Bender BS, Frank MM, Lawley TJ, Smith WJ, Brickman CM, Quinn TC. 1985. Defective reticuloendothelial systems Fc-receptor function in patients with acquired immunodeficiency syndrome. J Infect Dis 152:409–412.
Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248–254.
Dalgleish AG, Beverly PCL, Clapham PR, Crawford DH, Greaves WF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of receptor for the AIDS retrovirus. Nature (London) 312:763–767.
Estevez ME, Ballart IJ, Diez RA, Planes N, Scaglione C, Sen L. 1986. Early defect of phagocytic cell function in subjects at risk for acquired immunodeficiency syndrome. Scand J Immunol 24:215–221.
Fauci AS. 1984. Immunologic abnormalities in the acquired immunodeficiency syndrome (AIDS). Clin Res 32:491–499.
Gloeb DJ, Lai S, Efantis J, O’Sullivan MJ. 1992. Survival and disease progression in human immunodeficiency virus-infected women after an index delivery. Am J Obst Gyn 167:152–157.
Gougeon M-L, Colizzi V, Dalgleish A, Montagnier L. 1993. New concept in AIDS pathogenesis. AIDS Res Hum Retroviruses 9:287–289.
Hashida S, Ishikawa S, Hashinaka K, Nishikata I, Oka S, Ishikawa E. 2000. Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays. Clinical Diagnostic Lab Immunol 7:872–881.
Levine AM, Berhane K, Masri-Lavine L, Sanchez ML, Young M, AugenbraunM, Cohen M, Anastos K, Newman M, Gange SJ,Watts H. 2001. Prevalence and correlates of anemia in large cohort of HIV infected women: Women’s interagency HIV study. J Aquir Immune Defic Syndr 26:28–35.
Link RP, Perlman KL, Pierce EA, Schnoes HK, DeLuca HF. 1986. Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal Biochem 157:262–269.
McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RS. 1989. Evaluation of human and simian immunodeficiency virus plague and nerutralization assays. J Gen Virol 70:3327–3333.
Moller F, Rollag H, Froland SS. 1990.Reduced oxidative burst response in monocytes and monocyte-derived macrophages from HIVinfected subjects. Clin Exp Immunol 82:10–15.
Pos O, Stevenhagen OPA, Meenhorst PL, Kroon FP, VanFurth R. 1992. Impaired phagocytosis of Staphylococcus aureus by granulocytes and monocytes of AIDS patients. Exp Immunol 88:23–28.
Roux-Lombard P, Aladjem D, Balavoine J-F, ChofflonM, Despont J-P, Hirschel B, JeannetM, Kapanci Y, Lang R, Toccanier M-F, Voinier B, Wilhelm A, Dayer JM, Cruchaud A. 1986. Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy. Eur J Clin Invest 16:262–270.
Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Basler M, Massari F, Fox CH, Salzman NP, Fauci AS. 1989. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308.
Stein M,O’Sullivan P,Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G, Carpenter C, Skowron G,MayerK. 1992. Causes of deathin persons with human immunodeficiency virus infection. Am J Med 93:387–390.
Wendler I, Bienzle U, Hunsmann G. 1987.Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Human Retroviruses 3:157–163.
Bumet, M. Immunologic factors in the process of carcinogenesis. Br. Med. Bull., 20:154-158,1964.
Gross, L. Immunological defect in aged populations and its relationship to cancer. Cancer Res.18: 201-204,1965.
Freedman, H., and Ceglowski, W. Immunosuppression in the etiology of cancer. In: H. Freedman and W. Ceglowski (eds.), Immunological Aspects of Neoplasia, pp. 253-291. Baltimore: Williams & Wilkins, 1975.
Probert, J. C., Thompson, R. W., and Bagshow, M. A. Pattems of spread of distant metastases in head and neck cancer. Cancer (Phila.), 33: 127-133,1974.
Memo, 0. R., Lindberg. R. D., and Fletcher, G. H. An analysis of distant metastasis from squamous cell carcinoma of upper respiratory and digestive tracts. Cancer (Phila.), 1977.
Coppenhaver. D. H., Sllenne, N. P., and Bowman, B. H. Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). Arch. Biochem. Biophys., 226: 218-223,1983.
Viau, M., Constans, J., Debray, H., and Motreuil, J. Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. Biochem. Biophys. Res. Commun., 117: 324-331, 1983.
Lindberg, R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer (Phila.), 29: 1446-1449,1972.
Spiro, R. H., Alfonso, A., Fan, H. W., and Strong, E. M. Cervical node metastasis from epidermoid carcinoma of oral cavity and oropharynx. Am. J. Surg., 128:562-567, 1974.
Shafer, W. G., Hine, M. K., and Levy, B. M. A texthook of oral pathology, 4th Ed. Philadelphia: B. W. Saunders, 1983.
Hermanek, P., and Sabin, L. H. (eds.) Union Intemationale contre Ic Cancer: TNM of malignant tumors. Head and neck tumors. New York: Springer Verlag, 1987.
Kato, H., and Torigoe, T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer (Phila.), 40: 1621-1628,1977.
Bumet, M. Immunologic factors in the process of carcinogenesis. Br. Med. Bull., 20:154-158, 1964.
Bumet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res., 13:1-27,1970.
Fidler IJ. Therapy of disseminated melanoma by liposome-activated macrophages. World J Surg. 1992 Mar-Apr;16(2):270-6.
Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Rev. 1990 Feb;8(4):319-51.
Ray, R. Molecular recognition in vitamin D- binding protein. Proc Soc Exp Biol Med 212, 305–312, 1996.
Nguyen M, Shing Y, and Folkman J (1994). Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47, 31-40.
Swamy N, Roy A, Chang R, Brisson M, and Ray R (1995). Affinity purification of human plasma vitamin D-binding protein. Protein Expr Purif 6, 185-88.
Ono M, Torisu H, Fukushi J, Nishie A, and Kuwano M (1999). Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43(Suppl), 69 – 71.
Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, and Goerdt S (1997). Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197, 478 – 93. Neoplasia . Vol. 5, No. 1, 2003
Cao R, Farnebo J, Kurimoto M, and Cao Y (1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13, 2,195-202.
Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, and Folkman J (1995). Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87, 581–86.
Morton D, Eilber FR, Malmgren RA, and Wood WC (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158–63.
Weiner LM, Moldofsky PJ, Gatenby RA, O’Dwyer J, O’Brien J, Litwin S, and Comis RL (1980). Antibody delivery and effector cell activation in a phase II trial of recombinant gamma - interferon and the murine monoclonal antibody CO17- 1A in advanced colorectal carcinoma. Cancer Res 48, 2568–73.
Houghton AN, Mintzer D, Cordon - Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ (1985). Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82, 1242 – 46.
Kanda S, Mochizuki Y, Miyata Y, Kanetake H, and Yamamoto N (2002). Effects of vitamin-D3-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. JNCI 94, 1311-19.
Yamamoto N, Naraparaju VR, and Srinivasula SM (1995). Structural modification of serum vitamin -D3 binding protein and immunosuppression in HIV - infected patients. AIDS Res Hum Retroviruses 11, 1373-78.
Yang F, Bergeron JM, Linehan LA, Lalley PA, Sakaguchi AY, and Bowman BH (1990). Mapping and conservation of the group-specific component gene in mouse. Genomics 7, 509-16.
Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, and Popoff SN (1994). A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 152, 5100-07.
O’Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689-92.
Boehm T, Folkman J, Browder T, and O’Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
Hancock, JT, Malyt, F, Owen T.G. JONES, S. Properties of the superoxide-generating oxidase of B-lymphocyte cell lines Biochem. J. (1989) 262, 373-375.
AMAS articles—most authored by Samuel Bogoch, M.D. PhD.
Astrocytin and malignin: Two Polypeptide Fragments (Recognins) Related to Brain Tumor. National Cancer Institute Mon. 46:133-137, 1977.
Disarmed anti-malignin antibody in human cancer. Lancet. 1979 May 5;1(8123):987.
Monoclonal Anti-Malignin Antibodies. The Lancet 2:141-142, 1981.
Determination of Anti-Malignin Antibody and Malignin in 1,026 Cancer Patients and Controls: Relation of Antibody to Survival. J. Medicine 13:49-69, 1982.
Anti-Malignin Antibody and Scantag. Protides Biol. Fluids 30:337-352, 1983.
Elevated Levels of Anti-Malignin Antibody are Quantitatively Related to Longer Survival in Cancer Patients. Protides Biol. Fluids 31:739-747, 1984.
In Vitro Production of the General Transformation Antibody Related to Survival in Human Cancer Patients: Anti-Malignin Antibody (AMA). Cancer Detection and Prevention 18:Number 5/6, 551, 1985.
Increased Accuracy of Anti-Malignin Antibody Determination in Unstored Sera Permits Screening” Cancer Detection and Prevention. 11:Number 1/2, 85, 1987.
In Vitro Production of the General Transformation Antibody Related to Survival in Human Cancer Patients: Antimalignin Antibody Cancer Detection and Prevention 12:313-320,1988.
Malignin antibody and early malignancy. The Lancet 337:977,1991.
Malignin Antibody Returns to Normal After Successful Treatment of Breast Cancer. Cancer Detection and Prevention 17(l):180,1993.
Malignin Antibody As Early Warning. Cancer Detection and Prevention 17(l): 229,1993.
Comparison of Antimalignin With Other Markers for Early Detection and Surrogate Endpoint Use in Chemoprevention Trials for Breast, Colon, and Prostate Cancer. J. Cell Biochem. 19:61,1994 (National Cancer Institute Symposium)
Early Detection and Monitoring of Cancer with the Anti-Malignin Antibody Test. Detection and Prevention: 18(l):65-78,1994.
A Checklist for Suitability of Biomarkers as Surrogate Endpoints in Chemoprevention of Breast Cancer. J. Cell. Biochem 19:172-185,1994. (National Cancer Institute Symposium)
Aglyco Pathology of Viral Receptors in Dementias. In Functional Diversity of Interacting Receptors. New York Academy of Sciences 757:413-417,1995.
Return of Elevated Antimalignin Antibody to Normal Indicates Remission of Breast Cancer. American Association for Cancer Research 37:486,1996.
Antimalignin Antibody (AMAS®) Elevation Detects Persistent or Recurrent Breast Cancer. Cancer Detection and Prevention 20(5):508-509,1996.
A New Era for Cancer Diagnosis and Treatment Based Upon Earlier, Asymptomatic, Detection. J. Adv. Med. 10:149-150,1997.
Production of a Synthetic General Cancer Vaccine Which Augments the Concentration of Antimalignin Antibody In Vivo. Cancer Detection and Prevention 22(l):S-227,1998.
A Quantitative Immune Response in Human Cancer. Cancer Detection and Prevention 22(l):S-159,1998.
Nobuto Yamamoto, Naofumi, Ushijima, and Yoshihiko Koga. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). Serum Gc protein (known as vitamin D3-binding protein) is the precursor. J Med Virol. Jan; 81(1):16-26. 2009.
Yamamoto N, Suyama H, Nakazato H, Yamamoto N-Y, Koga Y. 2008c. Immunotherapy of metastatic colorectal cancer with vitamin Dbinding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 57:1007–1016.
Yamamoto N, Suyama H, Yamamoto N-Y. 2008b. Immunotherapy of prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Translational Oncol 1:65–72.
Yamamoto N, Suyama H, Yamamoto N-Y, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage-activating factor, (GcMAF). Int J Cancer 2008 Jan 15;122(2):461-7.
Yamamoto N, Ueda M, Benson CE. 2007. Treatment of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF) eradicates HIV-infection. Proc 13th Int Cong Immunol. Italy: Medimond, Bologna. pp. 35–38.
Nobuto Yamamoto, Masahiro Urade, Yoshihiko Koga, Nobuyuki Yamamoto, Theodor Sery and Masumi Ueda. Macrophages Activated By GCMAF Develop Enormous Variation of Receptors That Recognize and Eradicate Adenocarcinomas. Clinical Immunology, Volume 119, Supplement 1, 2006, Page S96. FOCIS 2006 Abstract Supplement - 6th Annual Meeting.
Yamamoto, Masahiro Urade, Yoshihiko Koga, Nobuyuki Yamamoto, Theodor Sery and Masumi Ueda. Macrophages Activated By GCMAF Develop Enormous Variation of Receptors That Recognize and Eradicate Adenocarcinomas. Nobuto 2006.
Yamamoto N.. Pathogenic significance of a-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Human Retroviruses 22:262–271, 2006.
Yamamoto N, Urade M. 2005. Pathogenic significance of a-Nacetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 7:674–681.
Yamamoto N, Urade M, Ueda M. 2005. Potent tumoricidal capacity of macrophages activated by Gc protein-derived macrophage activating factor (GcMAF) and its therapeutic efficacy for prostate, breast, and colorectal cancers. J Immunother 28:642.
Nobuto Yamamoto, Masahiro Urade. Microbes and infection. Institut Pasteur 7 , 4: 674-81, Apr 2005
Yamamoto N, Ueda M. 2004b. Eradication of HIV by treatment ofHIVinfected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology. Italy: Medmond, Bologna. pp. 197–200.
Yamamoto N, Ueda M. 2004a. Therapeutic efficacy of vitamin Dbinding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology. Italy: Medmond, Bologna. pp. 201–204.
Nobuto Yamamoto and Masumi Ueda. Cancer cell-killing by macrophages treated with Gc protein-derived macrophage activating factor (GcMAF) Proc Amer Assoc Cancer Res, Volume 45, 2004. Experimental and Molecular Therapeutics 11: Specific Immune Mechanisms and Cancer Vaccines: Clinical Studies Abstract #1255
Yamamoto N. 2002. Preparation of potent macrophage activating factor derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis. U.S. Patent Number: 6,410,269.
Shigeru Kanda, Yasushi Mochizuki, Yasuyoshi Miyata, Hiroshi Kanetake, Nobuto Yamamoto. Effects of Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) on Angiogenesis. Journal of the National Cancer Institute, Vol. 94, No. 17, 1311-1319, September 4, 2002.
Koga Y, Naraparaju VR, Yamamoto N. 1999. Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 220:20–26.
Yamamoto N. 1999. Diagnostic and prognostic ELISA assays of serum a-N-acetylgalactosaminidase for AIDS. U.S. Patent Number: 5,985,545.
Yamamoto N. 1998b. Diagnostic and prognostic ELISA assays of serum or plasma a-N-acetylgalactosaminidase for cancer. U.S. Patent Number: 5,712,104.
Yamamoto N, Naraparaju VR. 1998. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 76:237–244.
Yamamoto, Nabuto; Naraparaju, Venka Tenkateswara, R. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Special Feature. Immunology & Cell Biology. 76(3):237-244, June 1998.
Nobuto Yamamoto, Venkateswara R. Naraparaju and Masahiro Urade. Prognostic Utility of Serum a-N-Acetylgalactosaminidase and Immunosuppression Resulted from Deglycosylation of Serum Gc Protein in Oral Cancer Patients. Cancer Research 57, 295-299, January 15, 1997.
Yamamoto N. 1997. Diagnostic and prognostic indices for cancer and AIDS. U.S. Patent Number: 5,620,846. Yamamoto N. 1998a. Vitamin D and the immune system. In: Encyclopedia of Immunology. 2nd edition. Delves PJ, Roitt I, editors. Academic Press Ltd. London: pp. 2494–2499.
Yamamoto N, Naraparaju VR, Urade M. 1997. Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57:295–299.
Yamamoto N, Naraparaju VR. 1997. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D3-binding proteinderived macrophage activating factor. Cancer Res 57:2187–2192.
Nobuto Yamamoto, Venkateswara R. Naraparaju, Mary Moore and Lawrence H. Brent. Deglycosylation of Serum Vitamin D3-Binding Protein by alpha-N Acetylgalactosaminidase Detected in the Plasma of Patients with Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology Volume 82, Issue 3, March 1997, Pages 290-298.
Korbelik M, Naraparaju VR, and Yamamoto N (1997). Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75, 202 – 207.
Yamamoto, N., Naraparaju, V. R., and Asbell, S. 0. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res.,56:2827-2831,1996.
Yamamoto, N., and Naraparaju, V. R. Role of mouse vitamin D3-binding protein in activationof macrophages. J. Immunol.,157: 1744-1751,1996.
Yamamoto N. 1996. Structural definition of a potent macrophage activating factor derived from vitamin D3 binding protein with adjuvant activity for antibody production. Mol Immunol 33:1157–1164.
Koga, Y., Naraparaju, V. R., and Yamamoto, N. Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Cancer Research Proc., 37: 481, 1996.
Yamamoto, N., Naraparaju, V. R., and Srinivasula, S. M. Structural modification of serum vitamin D1-binding protein and immunosuppression in AIDS patients. AIDS Ret. Hum. Retroviruses, 11: 1373-1378,1995.
Yamamoto. N., Willen, N. P., and Lindsay, D. D. Participation of serum proteins in the inflammation-primed activation of macrophages.Inflammation, 8: 311-322, 1994.
Naraparaju VR, Yamamoto N. 1994. Roles of b-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation primed activation of macrophages. Immunol Lett 43:143–148.
Yamamoto N, Kumashiro R.. Conversion of vitamin D3 binding protein (Group! specific component) to a macrophage activating factor by the stepwise action of b-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794–2802, 1993.
Yamamoto N. 1993. In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor. U.S. Patent Number: 5,177,002.
Homma, S., Yamamoto, M., and Yamamoto, N. Vitamin D binding protein (group specific componen is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol. Cell Biol.,71: 249-257, 1993.
Yamamoto, N., Kumashiro, R., Yamamoto, M., Willett, N. P., and Lindsay, D. D. Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Inf. Imm., 61: 5388-5391, 1993.
Yamamoto, N., and Homma, S. Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes.Proc. NatI. Acad. Sci. USA, 88: 8539-8543, 1991.
Yamamoto N, Homma S, Millman I. 1991. Identification of the serum factor required for in vitro activation of macrophages: Role of vitamin D3 binding protein (Group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147:273–280.
Yamamoto N, Homma S. 1991. Vitamin D3 binding protein (groupspecific component,Gc) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88:539–543.
Homma S, Yamamoto N. 1990. Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 79:307–313.
Ngwenya, B. Z., and Yamamoto, N. Contribution of lysophosphatidylcholine-treated nonadherent cells to mechanism of macrophage activation. Proc. Soc. Exp. Biol. Med.,193:118-124, 1990.
Yamamoto N, St., Claire DA, Homma S, Ngwenya BZ. 1988. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 48:6044–6049.
Matsui T, Nakashima H, Yoshiyama H, Kobayashi N, Yamamoto N. 1987. Plaque staining assay for non- or weakly cytotoxic human immunodeficiency virus. J Clin Microbiol 25:1305–1307.
Yamamoto, N., Ngwenya, B. Z., Sery, 1. W., and Pieringer R. A. Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol. Immunother. 2,5: 185-192, 1987.
Yamamoto, N., and Ngwenya, B. Z. Activation of macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids. Cancer Res., 47: 2008-2013,1987.
Ngwenya, B. Z., and Yamamoto N. Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol. Immunother., 21: 1074-1082, 1986.
Harada S, Purtilo D, Koyanagi Y, Sonnabend J, Yamamoto N. 1986. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV). J Immnol Methods 92:177–181.
Ngwenya, B. Z., and Yamamoto, N. Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim. Biophys. Acts 839: 9-15,1985.
Sato M, Tanaka H, Yamada T, Yamamoto N. 1977. Persistent infection of BHK/WI-2 cells with rubella virus and characterization rubella variants. Arch Virol 54:333–343.
Korbelik M, Naraparaju VR, and Yamamoto N (1997). Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75, 202 – 207.
Yamamoto N, and Homma S (1991). Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88, 8539 – 43.
Yamamoto N, Hoober JK, Yamamoto N, and Yamamoto S (1992). Tumoricidal capacities of macrophages photodynamically activated with hematoporphoryin derivative. Photochem Photobiol 56, 245 – 50.
Yamamoto N, and Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D- binding protein -derived macrophage activating factor. Cancer Res 57, 2187–92, 1997.
Koga Y, Naraparaju VR, and Yamamoto N (1999). Antitumor effect of vitamin D- binding protein - derived macrophage activating factor on Ehrlich ascites tumor - bearing mice. Proc Soc Exp Biol Med 220, 20–26.
Other references
Fidler IJ. Therapy of disseminated melanoma by liposome-activated macrophages. World J Surg. 1992 Mar-Apr;16(2):270-6.
Fidler IJ. Macrophage therapy of cancer metastasis. Ciba Found Symp. 1988;141:211-22.
Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Ther. 1998 Jun;78(3):141-54.
Killion JJ, Fidler IJ. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Immunomethods. 1994 Jun;4(3):273-9.
Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 1998 Mar;17(1):55-75.
Liposomal delivery of biological response modifiers to macrophages. Pak CC, Fidler IJ. Biotherapy. 1991;3(1):55-64.
Macrophages in cancer metastases and their relevance to metastatic growth. Key ME. Cancer Metastasis Rev. 1983;2(1):75-88.
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38.
Drug delivery to macrophages for the therapy of cancer and infectious diseases. Kirsh R, Bugelski PJ, Poste G. Ann N Y Acad Sci. 1987;507:141-54. Review.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
Origin of cancer metastases and its implications for therapy. Fidler IJ. Isr J Med Sci. 1988 Sep-Oct;24(9-10):456-63.
Poste G. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep. 1986 Jan;70(1):183-99. Review.
Tumor cell diversity and host responses in cancer metastasis—part II—host immune responses and therapy of metastases. Nicolson GL, Poste G. Curr Probl Cancer. 1983 Jan;7(7):1-42. Review.
Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol. 1996 Jun;59(6):797-803.
Withers HR, Lee SP. Semin. Modeling growth kinetics and statistical distribution of oligometastases. Radiat Oncol. 2006 Apr;16(2):111-9.
Fidler IJ, Poste G. Springer Semin. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Immunopathol. 1982;5(2):161-74. Review.
Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol. 1999;43 Suppl:S3-10.
Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005 Jan;173(1):10-20.
Bender BS, Frank MM, Lawley TJ, Smith WJ, Brickman CM, Quinn TC. 1985. Defective reticuloendothelial systems Fc-receptor function in patients with acquired immunodeficiency syndrome. J Infect Dis 152:409–412.
Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248–254.
Dalgleish AG, Beverly PCL, Clapham PR, Crawford DH, Greaves WF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of receptor for the AIDS retrovirus. Nature (London) 312:763–767.
Estevez ME, Ballart IJ, Diez RA, Planes N, Scaglione C, Sen L. 1986. Early defect of phagocytic cell function in subjects at risk for acquired immunodeficiency syndrome. Scand J Immunol 24:215–221.
Fauci AS. 1984. Immunologic abnormalities in the acquired immunodeficiency syndrome (AIDS). Clin Res 32:491–499.
Gloeb DJ, Lai S, Efantis J, O’Sullivan MJ. 1992. Survival and disease progression in human immunodeficiency virus-infected women after an index delivery. Am J Obst Gyn 167:152–157.
Gougeon M-L, Colizzi V, Dalgleish A, Montagnier L. 1993. New concept in AIDS pathogenesis. AIDS Res Hum Retroviruses 9:287–289.
Hashida S, Ishikawa S, Hashinaka K, Nishikata I, Oka S, Ishikawa E. 2000. Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays. Clinical Diagnostic Lab Immunol 7:872–881.
Levine AM, Berhane K, Masri-Lavine L, Sanchez ML, Young M, AugenbraunM, Cohen M, Anastos K, Newman M, Gange SJ,Watts H. 2001. Prevalence and correlates of anemia in large cohort of HIV infected women: Women’s interagency HIV study. J Aquir Immune Defic Syndr 26:28–35.
Link RP, Perlman KL, Pierce EA, Schnoes HK, DeLuca HF. 1986. Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal Biochem 157:262–269.
McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RS. 1989. Evaluation of human and simian immunodeficiency virus plague and nerutralization assays. J Gen Virol 70:3327–3333.
Moller F, Rollag H, Froland SS. 1990.Reduced oxidative burst response in monocytes and monocyte-derived macrophages from HIVinfected subjects. Clin Exp Immunol 82:10–15.
Pos O, Stevenhagen OPA, Meenhorst PL, Kroon FP, VanFurth R. 1992. Impaired phagocytosis of Staphylococcus aureus by granulocytes and monocytes of AIDS patients. Exp Immunol 88:23–28.
Roux-Lombard P, Aladjem D, Balavoine J-F, ChofflonM, Despont J-P, Hirschel B, JeannetM, Kapanci Y, Lang R, Toccanier M-F, Voinier B, Wilhelm A, Dayer JM, Cruchaud A. 1986. Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy. Eur J Clin Invest 16:262–270.
Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Basler M, Massari F, Fox CH, Salzman NP, Fauci AS. 1989. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308.
Stein M,O’Sullivan P,Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G, Carpenter C, Skowron G,MayerK. 1992. Causes of deathin persons with human immunodeficiency virus infection. Am J Med 93:387–390.
Wendler I, Bienzle U, Hunsmann G. 1987.Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Human Retroviruses 3:157–163.
Bumet, M. Immunologic factors in the process of carcinogenesis. Br. Med. Bull., 20:154-158,1964.
Gross, L. Immunological defect in aged populations and its relationship to cancer. Cancer Res.18: 201-204,1965.
Freedman, H., and Ceglowski, W. Immunosuppression in the etiology of cancer. In: H. Freedman and W. Ceglowski (eds.), Immunological Aspects of Neoplasia, pp. 253-291. Baltimore: Williams & Wilkins, 1975.
Probert, J. C., Thompson, R. W., and Bagshow, M. A. Pattems of spread of distant metastases in head and neck cancer. Cancer (Phila.), 33: 127-133,1974.
Memo, 0. R., Lindberg. R. D., and Fletcher, G. H. An analysis of distant metastasis from squamous cell carcinoma of upper respiratory and digestive tracts. Cancer (Phila.), 1977.
Coppenhaver. D. H., Sllenne, N. P., and Bowman, B. H. Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). Arch. Biochem. Biophys., 226: 218-223,1983.
Viau, M., Constans, J., Debray, H., and Motreuil, J. Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. Biochem. Biophys. Res. Commun., 117: 324-331, 1983.
Lindberg, R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer (Phila.), 29: 1446-1449,1972.
Spiro, R. H., Alfonso, A., Fan, H. W., and Strong, E. M. Cervical node metastasis from epidermoid carcinoma of oral cavity and oropharynx. Am. J. Surg., 128:562-567, 1974.
Shafer, W. G., Hine, M. K., and Levy, B. M. A texthook of oral pathology, 4th Ed. Philadelphia: B. W. Saunders, 1983.
Hermanek, P., and Sabin, L. H. (eds.) Union Intemationale contre Ic Cancer: TNM of malignant tumors. Head and neck tumors. New York: Springer Verlag, 1987.
Kato, H., and Torigoe, T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer (Phila.), 40: 1621-1628,1977.
Bumet, M. Immunologic factors in the process of carcinogenesis. Br. Med. Bull., 20:154-158, 1964.
Bumet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res., 13:1-27,1970.
Fidler IJ. Therapy of disseminated melanoma by liposome-activated macrophages. World J Surg. 1992 Mar-Apr;16(2):270-6.
Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Rev. 1990 Feb;8(4):319-51.
Ray, R. Molecular recognition in vitamin D- binding protein. Proc Soc Exp Biol Med 212, 305–312, 1996.
Nguyen M, Shing Y, and Folkman J (1994). Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47, 31-40.
Swamy N, Roy A, Chang R, Brisson M, and Ray R (1995). Affinity purification of human plasma vitamin D-binding protein. Protein Expr Purif 6, 185-88.
Ono M, Torisu H, Fukushi J, Nishie A, and Kuwano M (1999). Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43(Suppl), 69 – 71.
Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, and Goerdt S (1997). Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197, 478 – 93. Neoplasia . Vol. 5, No. 1, 2003
Cao R, Farnebo J, Kurimoto M, and Cao Y (1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13, 2,195-202.
Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, and Folkman J (1995). Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87, 581–86.
Morton D, Eilber FR, Malmgren RA, and Wood WC (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158–63.
Weiner LM, Moldofsky PJ, Gatenby RA, O’Dwyer J, O’Brien J, Litwin S, and Comis RL (1980). Antibody delivery and effector cell activation in a phase II trial of recombinant gamma - interferon and the murine monoclonal antibody CO17- 1A in advanced colorectal carcinoma. Cancer Res 48, 2568–73.
Houghton AN, Mintzer D, Cordon - Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ (1985). Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82, 1242 – 46.
Kanda S, Mochizuki Y, Miyata Y, Kanetake H, and Yamamoto N (2002). Effects of vitamin-D3-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. JNCI 94, 1311-19.
Yamamoto N, Naraparaju VR, and Srinivasula SM (1995). Structural modification of serum vitamin -D3 binding protein and immunosuppression in HIV - infected patients. AIDS Res Hum Retroviruses 11, 1373-78.
Yang F, Bergeron JM, Linehan LA, Lalley PA, Sakaguchi AY, and Bowman BH (1990). Mapping and conservation of the group-specific component gene in mouse. Genomics 7, 509-16.
Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, and Popoff SN (1994). A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 152, 5100-07.
O’Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689-92.
Boehm T, Folkman J, Browder T, and O’Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
Hancock, JT, Malyt, F, Owen T.G. JONES, S. Properties of the superoxide-generating oxidase of B-lymphocyte cell lines Biochem. J. (1989) 262, 373-375.
AMAS articles—most authored by Samuel Bogoch, M.D. PhD.
Astrocytin and malignin: Two Polypeptide Fragments (Recognins) Related to Brain Tumor. National Cancer Institute Mon. 46:133-137, 1977.
Disarmed anti-malignin antibody in human cancer. Lancet. 1979 May 5;1(8123):987.
Monoclonal Anti-Malignin Antibodies. The Lancet 2:141-142, 1981.
Determination of Anti-Malignin Antibody and Malignin in 1,026 Cancer Patients and Controls: Relation of Antibody to Survival. J. Medicine 13:49-69, 1982.
Anti-Malignin Antibody and Scantag. Protides Biol. Fluids 30:337-352, 1983.
Elevated Levels of Anti-Malignin Antibody are Quantitatively Related to Longer Survival in Cancer Patients. Protides Biol. Fluids 31:739-747, 1984.
In Vitro Production of the General Transformation Antibody Related to Survival in Human Cancer Patients: Anti-Malignin Antibody (AMA). Cancer Detection and Prevention 18:Number 5/6, 551, 1985.
Increased Accuracy of Anti-Malignin Antibody Determination in Unstored Sera Permits Screening” Cancer Detection and Prevention. 11:Number 1/2, 85, 1987.
In Vitro Production of the General Transformation Antibody Related to Survival in Human Cancer Patients: Antimalignin Antibody Cancer Detection and Prevention 12:313-320,1988.
Malignin antibody and early malignancy. The Lancet 337:977,1991.
Malignin Antibody Returns to Normal After Successful Treatment of Breast Cancer. Cancer Detection and Prevention 17(l):180,1993.
Malignin Antibody As Early Warning. Cancer Detection and Prevention 17(l): 229,1993.
Comparison of Antimalignin With Other Markers for Early Detection and Surrogate Endpoint Use in Chemoprevention Trials for Breast, Colon, and Prostate Cancer. J. Cell Biochem. 19:61,1994 (National Cancer Institute Symposium)
Early Detection and Monitoring of Cancer with the Anti-Malignin Antibody Test. Detection and Prevention: 18(l):65-78,1994.
A Checklist for Suitability of Biomarkers as Surrogate Endpoints in Chemoprevention of Breast Cancer. J. Cell. Biochem 19:172-185,1994. (National Cancer Institute Symposium)
Aglyco Pathology of Viral Receptors in Dementias. In Functional Diversity of Interacting Receptors. New York Academy of Sciences 757:413-417,1995.
Return of Elevated Antimalignin Antibody to Normal Indicates Remission of Breast Cancer. American Association for Cancer Research 37:486,1996.
Antimalignin Antibody (AMAS®) Elevation Detects Persistent or Recurrent Breast Cancer. Cancer Detection and Prevention 20(5):508-509,1996.
A New Era for Cancer Diagnosis and Treatment Based Upon Earlier, Asymptomatic, Detection. J. Adv. Med. 10:149-150,1997.
Production of a Synthetic General Cancer Vaccine Which Augments the Concentration of Antimalignin Antibody In Vivo. Cancer Detection and Prevention 22(l):S-227,1998.
A Quantitative Immune Response in Human Cancer. Cancer Detection and Prevention 22(l):S-159,1998.
https://gcmaf.se/
http://www.ageofautism.com/2011/10/dr-bradstreet-nagalase-and-the-viral-issue-in-autism.html
Why the MHRA is corrupt
- the Medicines and Healthcare Regulatory Agency
Their remit: To protect the British from big pharmaceutical corporations and their drugs; To support new treatments
But with big pharma Directors on the MHRA's board
It actually protects billions of big pharma profits
At the expense of 200,000 British lives a year
10 public bodies state the MHRA is corrupt.
13,000 have petitioned to disband the MHRA
It licenses drugs that kill,
And denies the British good, inexpensive treatments
Under the MHRA, 160,000 British die of cancer annually
The MHRA has the worst cancer results in Western Europe
The MHRA banned GcMAF, the body’s way of curing cancer with no side effects. It has 300 GcMAF scientists
The MHRA helped conceal GcMAF for 26 years
They destroyed Britain’s GcMAF Co., Immuno Biotech Ltd
Got Immuno Biotech’s scientists and doctors fired
Got its CEO, David Noakes, arrested
https://mhracorrupt.st/
- the Medicines and Healthcare Regulatory Agency
Their remit: To protect the British from big pharmaceutical corporations and their drugs; To support new treatments
But with big pharma Directors on the MHRA's board
It actually protects billions of big pharma profits
At the expense of 200,000 British lives a year
10 public bodies state the MHRA is corrupt.
13,000 have petitioned to disband the MHRA
It licenses drugs that kill,
And denies the British good, inexpensive treatments
Under the MHRA, 160,000 British die of cancer annually
The MHRA has the worst cancer results in Western Europe
The MHRA banned GcMAF, the body’s way of curing cancer with no side effects. It has 300 GcMAF scientists
The MHRA helped conceal GcMAF for 26 years
They destroyed Britain’s GcMAF Co., Immuno Biotech Ltd
Got Immuno Biotech’s scientists and doctors fired
Got its CEO, David Noakes, arrested
https://mhracorrupt.st/
pubmed
Best matches for gcmaf:The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages.Siniscalco D et al. J Neuroinflammation. (2014)
Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.Morucci G et al. Anticancer Drugs. (2015)
Clinical experience of integrative cancer immunotherapy with GcMAF.Inui T et al. Anticancer Res. (2013)
Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.Morucci G et al. Anticancer Drugs. (2015)
Clinical experience of integrative cancer immunotherapy with GcMAF.Inui T et al. Anticancer Res. (2013)
Items: 1 to 20 of 68<< First< PrevPage of 4Next >Last >>
Select item 287820901.Purified umbilical cord derived mesenchymal stem cell treatment in a case of systemic lupus erythematosus.
Phillips CD, Wongsaisri P, Htut T, Grossman T.
Clin Transl Med. 2017 Dec;6(1):31. doi: 10.1186/s40169-017-0161-6. Epub 2017 Aug 7.
PMID:
28782090
Free PMC ArticleSimilar articles
Select item 275152182.Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)?
Ruggiero M, Reinwald H, Pacini S.
Med Hypotheses. 2016 Sep;94:126-31. doi: 10.1016/j.mehy.2016.07.012. Epub 2016 Jul 19.
PMID:
27515218Similar articles
Select item 275038033.Glycan structure of Gc Protein-derived Macrophage Activating Factor as revealed by mass spectrometry.
Borges CR, Rehder DS.
Arch Biochem Biophys. 2016 Sep 15;606:167-79. doi: 10.1016/j.abb.2016.08.006. Epub 2016 Aug 5.
PMID:
27503803Similar articles
Select item 273546534.Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
Inui T, Katsuura G, Kubo K, Kuchiike D, Chenery L, Uto Y, Nishikata T, Mette M.
Anticancer Res. 2016 Jul;36(7):3771-4.
PMID:
27354653Similar articles
Select item 273546525.Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Inui T, Amitani H, Kubo K, Kuchiike D, Uto Y, Nishikata T, Mette M.
Anticancer Res. 2016 Jul;36(7):3767-70.
PMID:
27354652Similar articles
Select item 271413546.Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.
Hamilton G, Rath B, Klameth L, Hochmair MJ.
Oncoimmunology. 2015 Oct 29;5(3):e1093277. eCollection 2016 Mar.
PMID:
27141354
Free PMC ArticleSimilar articles
Select item 268816637.The use of Gc protein-derived macrophage activating factor for management of thyroid cancer.
Chaiyasit K, Toshio I, Wiwanitkit V.
J Cancer Res Ther. 2015 Oct-Dec;11(4):1041. doi: 10.4103/0973-1482.151448. No abstract available.
PMID:
26881663
Free ArticleSimilar articles
Select item 265224618.Behind the scenes of vitamin D binding protein: more than vitamin D binding.
Delanghe JR, Speeckaert R, Speeckaert MM.
Best Pract Res Clin Endocrinol Metab. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2. Review.
PMID:
26522461Similar articles
Select item 261684999.Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.
Inui T, Kubo K, Kuchiike D, Uto Y, Nishikata T, Sakamoto N, Mette M.
Anticancer Res. 2015 Aug;35(8):4545-9.
PMID:
26168499Similar articles
Select item 2616849110.Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production.
Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T.
Anticancer Res. 2015 Aug;35(8):4487-92.
PMID:
26168491Similar articles
Select item 2578291511.Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia.
Branca JJ, Morucci G, Malentacchi F, Gelmini S, Ruggiero M, Pacini S.
J Neurosci Res. 2015 Sep;93(9):1364-77. doi: 10.1002/jnr.23588. Epub 2015 Mar 18.
PMID:
25782915Similar articles
Select item 2530498712.Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.
Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di Cesare Mannelli L, Pacini S.
Anticancer Drugs. 2015 Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177.
PMID:
25304987Similar articles
Select item 2529745113.Retraction note to: immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
[No authors listed]
Cancer Immunol Immunother. 2014 Dec;63(12):1349. doi: 10.1007/s00262-014-1616-x. No abstract available.
PMID:
25297451Similar articles
Select item 2518039814.'Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)' by Yamamoto, N., Suyama, H., Yamamoto, N. and Ushijima, N.
[No authors listed]
Int J Cancer. 2014 Sep 15;135(6):1509. No abstract available.
PMID:
25180398Similar articles
Select item 2507510415.Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.
Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N.
Anticancer Res. 2014 Aug;34(8):4589-93. Erratum in: Anticancer Res. 2015 Apr;35(4):2477.
PMID:
25075104Similar articles
Select item 2507510216.A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T.
Anticancer Res. 2014 Aug;34(8):4577-81.
PMID:
25075102Similar articles
Select item 2505682017.Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et al.
Ugarte A, Bouche G, Meheus L.
Cancer Immunol Immunother. 2014 Dec;63(12):1347-8. doi: 10.1007/s00262-014-1587-y. Epub 2014 Jul 24. No abstract available.
PMID:
25056820
Free PMC ArticleSimilar articles
Select item 2498237118.Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer.
Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S.
Anticancer Res. 2014 Jul;34(7):3569-78.
PMID:
24982371Similar articles
Select item 2473918719.The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages.
Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N.
J Neuroinflammation. 2014 Apr 17;11:78. doi: 10.1186/1742-2094-11-78.
PMID:
24739187
Free PMC ArticleSimilar articles
Select item 2417970820.GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.
Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S.
Oncoimmunology. 2013 Aug 1;2(8):e25769. Epub 2013 Jul 29.
PMID:
24179708
Free PMC ArticleSimilar articles
Select item 287820901.Purified umbilical cord derived mesenchymal stem cell treatment in a case of systemic lupus erythematosus.
Phillips CD, Wongsaisri P, Htut T, Grossman T.
Clin Transl Med. 2017 Dec;6(1):31. doi: 10.1186/s40169-017-0161-6. Epub 2017 Aug 7.
PMID:
28782090
Free PMC ArticleSimilar articles
Select item 275152182.Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)?
Ruggiero M, Reinwald H, Pacini S.
Med Hypotheses. 2016 Sep;94:126-31. doi: 10.1016/j.mehy.2016.07.012. Epub 2016 Jul 19.
PMID:
27515218Similar articles
Select item 275038033.Glycan structure of Gc Protein-derived Macrophage Activating Factor as revealed by mass spectrometry.
Borges CR, Rehder DS.
Arch Biochem Biophys. 2016 Sep 15;606:167-79. doi: 10.1016/j.abb.2016.08.006. Epub 2016 Aug 5.
PMID:
27503803Similar articles
Select item 273546534.Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
Inui T, Katsuura G, Kubo K, Kuchiike D, Chenery L, Uto Y, Nishikata T, Mette M.
Anticancer Res. 2016 Jul;36(7):3771-4.
PMID:
27354653Similar articles
Select item 273546525.Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Inui T, Amitani H, Kubo K, Kuchiike D, Uto Y, Nishikata T, Mette M.
Anticancer Res. 2016 Jul;36(7):3767-70.
PMID:
27354652Similar articles
Select item 271413546.Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.
Hamilton G, Rath B, Klameth L, Hochmair MJ.
Oncoimmunology. 2015 Oct 29;5(3):e1093277. eCollection 2016 Mar.
PMID:
27141354
Free PMC ArticleSimilar articles
Select item 268816637.The use of Gc protein-derived macrophage activating factor for management of thyroid cancer.
Chaiyasit K, Toshio I, Wiwanitkit V.
J Cancer Res Ther. 2015 Oct-Dec;11(4):1041. doi: 10.4103/0973-1482.151448. No abstract available.
PMID:
26881663
Free ArticleSimilar articles
Select item 265224618.Behind the scenes of vitamin D binding protein: more than vitamin D binding.
Delanghe JR, Speeckaert R, Speeckaert MM.
Best Pract Res Clin Endocrinol Metab. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2. Review.
PMID:
26522461Similar articles
Select item 261684999.Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.
Inui T, Kubo K, Kuchiike D, Uto Y, Nishikata T, Sakamoto N, Mette M.
Anticancer Res. 2015 Aug;35(8):4545-9.
PMID:
26168499Similar articles
Select item 2616849110.Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production.
Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T.
Anticancer Res. 2015 Aug;35(8):4487-92.
PMID:
26168491Similar articles
Select item 2578291511.Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia.
Branca JJ, Morucci G, Malentacchi F, Gelmini S, Ruggiero M, Pacini S.
J Neurosci Res. 2015 Sep;93(9):1364-77. doi: 10.1002/jnr.23588. Epub 2015 Mar 18.
PMID:
25782915Similar articles
Select item 2530498712.Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.
Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di Cesare Mannelli L, Pacini S.
Anticancer Drugs. 2015 Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177.
PMID:
25304987Similar articles
Select item 2529745113.Retraction note to: immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
[No authors listed]
Cancer Immunol Immunother. 2014 Dec;63(12):1349. doi: 10.1007/s00262-014-1616-x. No abstract available.
PMID:
25297451Similar articles
Select item 2518039814.'Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)' by Yamamoto, N., Suyama, H., Yamamoto, N. and Ushijima, N.
[No authors listed]
Int J Cancer. 2014 Sep 15;135(6):1509. No abstract available.
PMID:
25180398Similar articles
Select item 2507510415.Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.
Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N.
Anticancer Res. 2014 Aug;34(8):4589-93. Erratum in: Anticancer Res. 2015 Apr;35(4):2477.
PMID:
25075104Similar articles
Select item 2507510216.A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T.
Anticancer Res. 2014 Aug;34(8):4577-81.
PMID:
25075102Similar articles
Select item 2505682017.Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et al.
Ugarte A, Bouche G, Meheus L.
Cancer Immunol Immunother. 2014 Dec;63(12):1347-8. doi: 10.1007/s00262-014-1587-y. Epub 2014 Jul 24. No abstract available.
PMID:
25056820
Free PMC ArticleSimilar articles
Select item 2498237118.Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer.
Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S.
Anticancer Res. 2014 Jul;34(7):3569-78.
PMID:
24982371Similar articles
Select item 2473918719.The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages.
Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N.
J Neuroinflammation. 2014 Apr 17;11:78. doi: 10.1186/1742-2094-11-78.
PMID:
24739187
Free PMC ArticleSimilar articles
Select item 2417970820.GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.
Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S.
Oncoimmunology. 2013 Aug 1;2(8):e25769. Epub 2013 Jul 29.
PMID:
24179708
Free PMC ArticleSimilar articles
Search resultsItems: 21 to 40 of 68
<< First< PrevPage of 4Next >Last >>
Select item 2413550021.Vitamin D in endometriosis: a causative or confounding factor?
Sayegh L, Fuleihan Gel-H, Nassar AH.
Metabolism. 2014 Jan;63(1):32-41. doi: 10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review.
PMID:
24135500Similar articles
Select item 2385722822.A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.
Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S.
Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.
PMID:
23857228
Free PMC ArticleSimilar articles
Select item 2378098023.Clinical experience of integrative cancer immunotherapy with GcMAF.
Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N.
Anticancer Res. 2013 Jul;33(7):2917-9.
PMID:
23780980Similar articles
Select item 2378097924.Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung cancer in mice.
Hirota K, Nakagawa Y, Takeuchi R, Uto Y, Hori H, Onizuka S, Terada H.
Anticancer Res. 2013 Jul;33(7):2911-5.
PMID:
23780979Similar articles
Select item 2378097425.Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K, Mette M, Inui T, Endo Y, Hori H.
Anticancer Res. 2013 Jul;33(7):2881-5.
PMID:
23780974Similar articles
Select item 2284825026.Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line.
Toyohara Y, Hashitani S, Kishimoto H, Noguchi K, Yamamoto N, Urade M.
Oncol Lett. 2011 Jul;2(4):685-691. Epub 2011 May 13.
PMID:
22848250
Free PMC ArticleSimilar articles
Select item 2274016127.Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer.
Bellone M, Rigamonti N.
Cancer Immunol Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun 28. No abstract available.
PMID:
22740161Similar articles
Select item 2264167528.β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y, Yamamoto S, Mukai H, Ishiyama N, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Hori H.
Anticancer Res. 2012 Jun;32(6):2359-64.
PMID:
22641675Similar articles
Select item 2221328729.Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.
Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M.
Anticancer Res. 2012 Jan;32(1):45-52.
PMID:
22213287Similar articles
Select item 2195677130.Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S.
J Nephrol. 2012 Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035.
PMID:
21956771Similar articles
Select item 2187316431.Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Nakata E, Hori H.
Anticancer Res. 2011 Jul;31(7):2489-92.
PMID:
21873164Similar articles
Select item 2117064732.Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M.
Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14.
PMID:
21170647Similar articles
Select item 2097614133.Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.
Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S, Fannon M.
PLoS One. 2010 Oct 18;5(10):e13428. doi: 10.1371/journal.pone.0013428.
PMID:
20976141
Free PMC ArticleSimilar articles
Select item 2085508334.Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N, Kanematsu T, Fujioka H.
J Surg Res. 2012 Jan;172(1):116-22. doi: 10.1016/j.jss.2010.07.057. Epub 2010 Sep 17.
PMID:
20855083Similar articles
Select item 2007946735.The glycosylation and characterization of the candidate Gc macrophage activating factor.
Ravnsborg T, Olsen DT, Thysen AH, Christiansen M, Houen G, Højrup P.
Biochim Biophys Acta. 2010 Apr;1804(4):909-17. doi: 10.1016/j.bbapap.2009.12.022. Epub 2010 Jan 13.
PMID:
20079467Similar articles
Select item 1964215936.Glycosylation status of vitamin D binding protein in cancer patients.
Rehder DS, Nelson RW, Borges CR.
Protein Sci. 2009 Oct;18(10):2036-42. doi: 10.1002/pro.214.
PMID:
19642159
Free PMC ArticleSimilar articles
Select item 1903145137.Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).
Yamamoto N, Ushijima N, Koga Y.
J Med Virol. 2009 Jan;81(1):16-26. doi: 10.1002/jmv.21376. Retraction in: J Med Virol. 2014 Nov;86(11):1998.
PMID:
19031451Similar articles
Select item 1863346138.Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N, Suyama H, Yamamoto N.
Transl Oncol. 2008 Jul;1(2):65-72.
PMID:
18633461
Free PMC ArticleSimilar articles
Select item 1805809639.Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.
Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014 Dec;63(12):1349.
PMID:
18058096Similar articles
Select item 1793513040.Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N, Suyama H, Yamamoto N, Ushijima N.
Int J Cancer. 2008 Jan 15;122(2):461-7. Retraction in: Int J Cancer. 2014 Sep 15;135(6):1509.
PMID:
17935130
Free ArticleSimilar articles
<< First< PrevPage of 4Next >Last >>
Select item 2413550021.Vitamin D in endometriosis: a causative or confounding factor?
Sayegh L, Fuleihan Gel-H, Nassar AH.
Metabolism. 2014 Jan;63(1):32-41. doi: 10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review.
PMID:
24135500Similar articles
Select item 2385722822.A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.
Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S.
Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.
PMID:
23857228
Free PMC ArticleSimilar articles
Select item 2378098023.Clinical experience of integrative cancer immunotherapy with GcMAF.
Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N.
Anticancer Res. 2013 Jul;33(7):2917-9.
PMID:
23780980Similar articles
Select item 2378097924.Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung cancer in mice.
Hirota K, Nakagawa Y, Takeuchi R, Uto Y, Hori H, Onizuka S, Terada H.
Anticancer Res. 2013 Jul;33(7):2911-5.
PMID:
23780979Similar articles
Select item 2378097425.Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K, Mette M, Inui T, Endo Y, Hori H.
Anticancer Res. 2013 Jul;33(7):2881-5.
PMID:
23780974Similar articles
Select item 2284825026.Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line.
Toyohara Y, Hashitani S, Kishimoto H, Noguchi K, Yamamoto N, Urade M.
Oncol Lett. 2011 Jul;2(4):685-691. Epub 2011 May 13.
PMID:
22848250
Free PMC ArticleSimilar articles
Select item 2274016127.Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer.
Bellone M, Rigamonti N.
Cancer Immunol Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun 28. No abstract available.
PMID:
22740161Similar articles
Select item 2264167528.β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y, Yamamoto S, Mukai H, Ishiyama N, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Hori H.
Anticancer Res. 2012 Jun;32(6):2359-64.
PMID:
22641675Similar articles
Select item 2221328729.Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.
Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M.
Anticancer Res. 2012 Jan;32(1):45-52.
PMID:
22213287Similar articles
Select item 2195677130.Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S.
J Nephrol. 2012 Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035.
PMID:
21956771Similar articles
Select item 2187316431.Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Nakata E, Hori H.
Anticancer Res. 2011 Jul;31(7):2489-92.
PMID:
21873164Similar articles
Select item 2117064732.Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M.
Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14.
PMID:
21170647Similar articles
Select item 2097614133.Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.
Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S, Fannon M.
PLoS One. 2010 Oct 18;5(10):e13428. doi: 10.1371/journal.pone.0013428.
PMID:
20976141
Free PMC ArticleSimilar articles
Select item 2085508334.Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N, Kanematsu T, Fujioka H.
J Surg Res. 2012 Jan;172(1):116-22. doi: 10.1016/j.jss.2010.07.057. Epub 2010 Sep 17.
PMID:
20855083Similar articles
Select item 2007946735.The glycosylation and characterization of the candidate Gc macrophage activating factor.
Ravnsborg T, Olsen DT, Thysen AH, Christiansen M, Houen G, Højrup P.
Biochim Biophys Acta. 2010 Apr;1804(4):909-17. doi: 10.1016/j.bbapap.2009.12.022. Epub 2010 Jan 13.
PMID:
20079467Similar articles
Select item 1964215936.Glycosylation status of vitamin D binding protein in cancer patients.
Rehder DS, Nelson RW, Borges CR.
Protein Sci. 2009 Oct;18(10):2036-42. doi: 10.1002/pro.214.
PMID:
19642159
Free PMC ArticleSimilar articles
Select item 1903145137.Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).
Yamamoto N, Ushijima N, Koga Y.
J Med Virol. 2009 Jan;81(1):16-26. doi: 10.1002/jmv.21376. Retraction in: J Med Virol. 2014 Nov;86(11):1998.
PMID:
19031451Similar articles
Select item 1863346138.Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N, Suyama H, Yamamoto N.
Transl Oncol. 2008 Jul;1(2):65-72.
PMID:
18633461
Free PMC ArticleSimilar articles
Select item 1805809639.Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.
Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014 Dec;63(12):1349.
PMID:
18058096Similar articles
Select item 1793513040.Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N, Suyama H, Yamamoto N, Ushijima N.
Int J Cancer. 2008 Jan 15;122(2):461-7. Retraction in: Int J Cancer. 2014 Sep 15;135(6):1509.
PMID:
17935130
Free ArticleSimilar articles
Search resultsItems: 41 to 60 of 68
<< First< PrevPage of 4Next >Last >>
Select item 1673445041.A designed glycoprotein analogue of Gc-MAF exhibits native-like phagocytic activity.
Bogani F, McConnell E, Joshi L, Chang Y, Ghirlanda G.
J Am Chem Soc. 2006 Jun 7;128(22):7142-3.
PMID:
16734450Similar articles
Select item 1640052042.Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S, Brard L, Granai CO, Swamy N.
Angiogenesis. 2005;8(4):349-60. Epub 2006 Jan 7.
PMID:
16400520Similar articles
Select item 1630272743.Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.
Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, Kirk KL, Hori H.
Anticancer Res. 2005 Nov-Dec;25(6A):3689-95. Review.
PMID:
16302727
Free ArticleSimilar articles
Select item 1551543244.Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.
Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H.
Anticancer Res. 2004 Sep-Oct;24(5C):3361-6.
PMID:
15515432
Free ArticleSimilar articles
Select item 1508497945.Pancreatic carcinogenesis: apoptosis and angiogenesis.
Onizuka S, Kawakami S, Taniguchi K, Fujioka H, Miyashita K.
Pancreas. 2004 Apr;28(3):317-9.
PMID:
15084979Similar articles
Select item 1476753646.Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor.
Matsuura T, Uematsu T, Yamaoka M, Furusawa K.
Int J Oncol. 2004 Mar;24(3):521-8.
PMID:
14767536Similar articles
Select item 1469697447.The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone.
Schneider GB, Grecco KJ, Safadi FF, Popoff SN.
Crit Rev Eukaryot Gene Expr. 2003;13(2-4):277-84.
PMID:
14696974Similar articles
Select item 1466673348.Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.
Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H.
Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.
PMID:
14666733Similar articles
Select item 1293815949.Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages.
Gumireddy K, Reddy CD, Swamy N.
J Cell Biochem. 2003 Sep 1;90(1):87-96.
PMID:
12938159Similar articles
Select item 1265966850.Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.
Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S.
Neoplasia. 2003 Jan-Feb;5(1):32-40.
PMID:
12659668
Free PMC ArticleSimilar articles
Select item 1258040851.Characterization of human Gc protein-derived macrophage activation factor (GcMAF) and its functional role in macrophage tumoricidal activity.
Mohamad SB, Hori H, Nagasawa H, Usui K, Uto Y.
Adv Exp Med Biol. 2003;510:77-82. No abstract available.
PMID:
12580408Similar articles
Select item 1255307352.Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB, Nagasawa H, Uto Y, Hori H.
Anticancer Res. 2002 Nov-Dec;22(6C):4297-300.
PMID:
12553073Similar articles
Select item 1220889653.Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis.
Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N.
J Natl Cancer Inst. 2002 Sep 4;94(17):1311-9.
PMID:
12208896Similar articles
Select item 1206218454.Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.
Mohamad SB, Nagasawa H, Uto Y, Hori H.
Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8.
PMID:
12062184Similar articles
Select item 1125523655.Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity.
Swamy N, Ghosh S, Schneider GB, Ray R.
J Cell Biochem. 2001;81(3):535-46.
PMID:
11255236Similar articles
Select item 1045638256.The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF.
Odgren PR, Popoff SN, Safadi FF, MacKay CA, Mason-Savas A, Seifert MF, Marks SC Jr.
Bone. 1999 Aug;25(2):175-81.
PMID:
10456382Similar articles
Select item 989316457.Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.
Koga Y, Naraparaju VR, Yamamoto N.
Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6.
PMID:
9893164Similar articles
Select item 973119458.A possible new role for vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+ sensing at low physiological concentrations.
Adebanjo OA, Moonga BS, Haddad JG, Huang CL, Zaidi M.
Biochem Biophys Res Commun. 1998 Aug 28;249(3):668-71.
PMID:
9731194Similar articles
Select item 968296759.Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.
Yamamoto N, Naraparaju VR.
Immunol Cell Biol. 1998 Jun;76(3):237-44.
PMID:
9682967Similar articles
60.
Select item 9187119
Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N, Naraparaju VR.
Cancer Res. 1997 Jun 1;57(11):2187-92.
PMID:
9187119
Free ArticleSimilar articles
<< First< PrevPage of 4Next >Last >>
Select item 1673445041.A designed glycoprotein analogue of Gc-MAF exhibits native-like phagocytic activity.
Bogani F, McConnell E, Joshi L, Chang Y, Ghirlanda G.
J Am Chem Soc. 2006 Jun 7;128(22):7142-3.
PMID:
16734450Similar articles
Select item 1640052042.Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S, Brard L, Granai CO, Swamy N.
Angiogenesis. 2005;8(4):349-60. Epub 2006 Jan 7.
PMID:
16400520Similar articles
Select item 1630272743.Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.
Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, Kirk KL, Hori H.
Anticancer Res. 2005 Nov-Dec;25(6A):3689-95. Review.
PMID:
16302727
Free ArticleSimilar articles
Select item 1551543244.Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.
Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H.
Anticancer Res. 2004 Sep-Oct;24(5C):3361-6.
PMID:
15515432
Free ArticleSimilar articles
Select item 1508497945.Pancreatic carcinogenesis: apoptosis and angiogenesis.
Onizuka S, Kawakami S, Taniguchi K, Fujioka H, Miyashita K.
Pancreas. 2004 Apr;28(3):317-9.
PMID:
15084979Similar articles
Select item 1476753646.Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor.
Matsuura T, Uematsu T, Yamaoka M, Furusawa K.
Int J Oncol. 2004 Mar;24(3):521-8.
PMID:
14767536Similar articles
Select item 1469697447.The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone.
Schneider GB, Grecco KJ, Safadi FF, Popoff SN.
Crit Rev Eukaryot Gene Expr. 2003;13(2-4):277-84.
PMID:
14696974Similar articles
Select item 1466673348.Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.
Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H.
Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.
PMID:
14666733Similar articles
Select item 1293815949.Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages.
Gumireddy K, Reddy CD, Swamy N.
J Cell Biochem. 2003 Sep 1;90(1):87-96.
PMID:
12938159Similar articles
Select item 1265966850.Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.
Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S.
Neoplasia. 2003 Jan-Feb;5(1):32-40.
PMID:
12659668
Free PMC ArticleSimilar articles
Select item 1258040851.Characterization of human Gc protein-derived macrophage activation factor (GcMAF) and its functional role in macrophage tumoricidal activity.
Mohamad SB, Hori H, Nagasawa H, Usui K, Uto Y.
Adv Exp Med Biol. 2003;510:77-82. No abstract available.
PMID:
12580408Similar articles
Select item 1255307352.Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB, Nagasawa H, Uto Y, Hori H.
Anticancer Res. 2002 Nov-Dec;22(6C):4297-300.
PMID:
12553073Similar articles
Select item 1220889653.Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis.
Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N.
J Natl Cancer Inst. 2002 Sep 4;94(17):1311-9.
PMID:
12208896Similar articles
Select item 1206218454.Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.
Mohamad SB, Nagasawa H, Uto Y, Hori H.
Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8.
PMID:
12062184Similar articles
Select item 1125523655.Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity.
Swamy N, Ghosh S, Schneider GB, Ray R.
J Cell Biochem. 2001;81(3):535-46.
PMID:
11255236Similar articles
Select item 1045638256.The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF.
Odgren PR, Popoff SN, Safadi FF, MacKay CA, Mason-Savas A, Seifert MF, Marks SC Jr.
Bone. 1999 Aug;25(2):175-81.
PMID:
10456382Similar articles
Select item 989316457.Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.
Koga Y, Naraparaju VR, Yamamoto N.
Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6.
PMID:
9893164Similar articles
Select item 973119458.A possible new role for vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+ sensing at low physiological concentrations.
Adebanjo OA, Moonga BS, Haddad JG, Huang CL, Zaidi M.
Biochem Biophys Res Commun. 1998 Aug 28;249(3):668-71.
PMID:
9731194Similar articles
Select item 968296759.Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.
Yamamoto N, Naraparaju VR.
Immunol Cell Biol. 1998 Jun;76(3):237-44.
PMID:
9682967Similar articles
60.
Select item 9187119
Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N, Naraparaju VR.
Cancer Res. 1997 Jun 1;57(11):2187-92.
PMID:
9187119
Free ArticleSimilar articles
Search resultsItems: 61 to 68 of 68
<< First< PrevPage of 4Next >Last >>
Select item 907355361.Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Yamamoto N, Naraparaju VR, Moore M, Brent LH.
Clin Immunol Immunopathol. 1997 Mar;82(3):290-8.
PMID:
9073553Similar articles
Select item 901002762.Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer.
Korbelik M, Naraparaju VR, Yamamoto N.
Br J Cancer. 1997;75(2):202-7.
PMID:
9010027
Free PMC ArticleSimilar articles
Select item 887418663.The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats.
Benis KA, Schneider GB.
Blood. 1996 Oct 15;88(8):2898-905.
PMID:
8874186
Free ArticleSimilar articles
Select item 907066364.Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production.
Yamamoto N.
Mol Immunol. 1996 Oct;33(15):1157-64.
PMID:
9070663Similar articles
Select item 866552165.Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N, Naraparaju VR, Asbell SO.
Cancer Res. 1996 Jun 15;56(12):2827-31.
PMID:
8665521
Free ArticleSimilar articles
Select item 857339566.Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N, Naraparaju VR, Srinivasula SM.
AIDS Res Hum Retroviruses. 1995 Nov;11(11):1373-8.
PMID:
8573395Similar articles
Select item 766944367.Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations.
Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN.
Bone. 1995 Jun;16(6):657-62.
PMID:
7669443Similar articles
Select item 817622668.A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN.
J Immunol. 1994 May 15;152(10):5100-7.
PMID:
8176226Similar articles
<< First< PrevPage of 4Next >Last >>
Select item 907355361.Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.
Yamamoto N, Naraparaju VR, Moore M, Brent LH.
Clin Immunol Immunopathol. 1997 Mar;82(3):290-8.
PMID:
9073553Similar articles
Select item 901002762.Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer.
Korbelik M, Naraparaju VR, Yamamoto N.
Br J Cancer. 1997;75(2):202-7.
PMID:
9010027
Free PMC ArticleSimilar articles
Select item 887418663.The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats.
Benis KA, Schneider GB.
Blood. 1996 Oct 15;88(8):2898-905.
PMID:
8874186
Free ArticleSimilar articles
Select item 907066364.Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production.
Yamamoto N.
Mol Immunol. 1996 Oct;33(15):1157-64.
PMID:
9070663Similar articles
Select item 866552165.Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N, Naraparaju VR, Asbell SO.
Cancer Res. 1996 Jun 15;56(12):2827-31.
PMID:
8665521
Free ArticleSimilar articles
Select item 857339566.Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N, Naraparaju VR, Srinivasula SM.
AIDS Res Hum Retroviruses. 1995 Nov;11(11):1373-8.
PMID:
8573395Similar articles
Select item 766944367.Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations.
Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN.
Bone. 1995 Jun;16(6):657-62.
PMID:
7669443Similar articles
Select item 817622668.A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN.
J Immunol. 1994 May 15;152(10):5100-7.
PMID:
8176226Similar articles
